• If You Absolutely Must Vaccinate Against COVID-19 Out Of Fear Or Coercion, Hold Out For This Already Proven Vaccine

    Posted March 21, 2021: by Bill Sardi

    There is a reason why vaccine makers and bought-off politicians are racing to vaccinate 100 million Americans by July 4th. If prior population studies are any indication, by July 2021 it is likely a safer and more effective vaccine than RNA vaccines (Pfizer/Moderna) will be revealed in a large-group placebo vs inoculum study taking place in Canada.

    If you are in torment over whether to vaccinate against COVID-19 or not, or forced to mull over vaccination because your employer demands you submit to immunization as a condition of employment, hold on, at least till July 2021, when the results of a major vaccine study will likely be revealed. Though existing data is so compelling one would wonder why anyone fearful of COVID19 would hesitate to undergo immunization immediately.

    A major drawback of the RNA vaccines now being pushed upon wary Americans is that they pose the problem of antibody dependent enhancement (ADE) – – your own antibodies attack your lungs and other internal organs. ADE is usually a delayed reaction. And ADE is beginning to occur among vaccinated populations. ADE strikes younger populations. According to some reports, vaccine-induced antibodies against COVID-19 are not providing lasting immunity.

    Researchers suggest one answer to the problem of ADE is to design therapies that target T-cells rather than antibodies. RNA vaccines largely activate antibodies.

    T-cells are known to protect against severe infection and re-infection. T-cell memory provides lasting immunity. T-cell directed vaccines stimulate clearance of viruses and avoid antibody-dependent enhanced disease.

    These same researchers reveal there already is a proven safe and effective vaccine that protects against COVID-19 via activation of T-cells – – the Bacille Calmette-Guerin (BCG) vaccine for another infectious lung disease — tuberculosis. It is derived from a mycobacterium (mycobacterium bovis) found in cattle. It is a “live” but attenuated bacterium.

    BCG vaccine mechanism: trained immunity

    The BCG vaccine is not widely used in the US.

    While the BCG vaccine does activate T-cells, it also works independent of B or T cells. BCG vaccine affords “trained immunity.” It works via epigenetic re-programming, that is, gene protein making, which essentially what the RNA vaccines pretend to do. This is called epigenetic memory.

    This type of trained immunity is independent of B and T-cell activation and is accomplished via white blood cells (monocytes, macrophages, natural-killer cells). For physicians who must to know precisely how it works, BCG vaccine targets known cell surface receptors (toll-like TLR2 and TLR4; complement receptors CR3-CR4; NOD-like receptors).

    BCG vaccine is so safe it is approved for use with neonates, children and adults for almost 100 years.

    The BCG vaccine also confers immunity against Staphylococcus and Candida organisms in additional tuberculosis bacilli. BCG vaccine is also useful in preventing multiple sclerosis and cancer.

    BCG Vaccine and COVID-19

    Evidence for the BCG vaccine to quell COVID-19 infections is compelling.

    Worldwide, TB kills more people than COVID-19. Now “two birds could be knocked out with one stone.”

    Vaccine makers must inoculate many thousands of people with their unproven COVID-19 vaccines while population studies already show BCG to be superior and more affordable.

    Upcoming BCG vaccine trial to be completed soon

    A large BCG controlled trial of 3626 participants that compares BCG vaccine versus placebo and is expected to be complete in April, 2021 and reporting by July, 2021. This Canadian study encompasses measures of incidence of infection, hospitalization, respiratory distress, secondary infection and mortality, as well as adverse events and trained immunity, among healthcare workers.

    A six-month trial of BCG vaccine among health care workers is also being launched by the MD Anderson Cancer Center/Baylor College of Medicine and Cedars Sinai Medical Center.

    Improbability current COVID-19 vaccines will overcome ADE

    Dr. Kevin D Morris of the City of Hope says it is improbable that modern medicine will ever develop a vaccine for COVID-19 because any such vaccine must overcome antibody enhancement which attacks and replicates within the very cells (macrophages) that are produced to “kill” the virus.

    Fancy genetic RNA vaccines may ignite the production of antibodies without having to introduce a pathogenic virus as common vaccines do, which is advantageous. The threat of vaccine-induced infection is removed. But there is no stop sign for the development of organ-destructive antibody enhancement. This is why prior efforts to conquer coronavirus infections via vaccination failed.

    Vaccine makers are admitting a single inoculation won’t produce a lasting effect. Two doses are now employed and a third is being considered. The vaccinologists are begging for problematic antibody enhancement to occur by suggesting annual booster shots.

    How the virus enters cells

    It would behoove everyone to learn how viruses enter living cells.

    Viruses are not live. They need to get into living cells to replicate. Viral entry is confined to cells that have a surface protein the virus can attach to, in this instance, the angiotensin cleaving enzyme-2 (ACE2), a protein involved in the regulation of blood pressure. ACE2 is abundant in the eye, throat, lung, kidney, liver, heart and intestines. That is why this virus affects other organs than the lungs.

    Several viruses (dengue, HIV and COVID-19 coronavirus) can infect cells via an alternative process called antibody-dependent enhancement (ADE).

    Since 1986 it has been known that T-cells, not antibodies, are paramount in producing immunity. The natural defense against viruses, antibodies, are directed against the immune system. The virus attaches to white blood cells (monocytes, macrophages). Antibodies normally bind to viral surface proteins and block entry into cells. However, COVID-19 infected antibodies can worsen damage in the lungs. If a vaccine induces high levels of potentially neutralizing antibodies they will reduce viral replication but this could also result in lung damage. The structure and concentration of these antibodies determines their destructiveness.

    Human respiratory coronaviruses do not induce durable immunity. Reinfections are common. This is another reason why vaccines against coronaviruses have never been licensed. Antibody responses and protective immunity are fleeting and only modestly effective.

    Respiratory coronaviruses vex the human adaptive immune system
    and can return to the same person time after time

    says Dr. Andrea Branch of Icahn School of Medicine
    at Mt. Sinai in New York.

    Respiratory coronaviruses vex the human adaptive immune system and can return to the same person time after time” says Dr. Andrea Branch of Icahn School of Medicine at Mt. Sinai in New York.

    Initially viruses are met by natural killers – – neutrophils and macrophages, that kill virally-infected cells. Days after initial infection a more specific defense is fashioned by B and T cells produced in the bone marrow and thymus gland. These B and T cells are tailored to the particular invasive pathogen, in this case a coronavirus, and produce memory or long-lasting immunity. That is why individuals must suffer with cold virus symptoms for a few days before this specific immune response is activated.

    Antibodies against the antecedent SARS-CoV-1 virus that erupted in 2002 in China were not long lasting. They plunged after two years. B cells didn’t remain but memory T-cells did endure.

    Theoretically, a coronavirus like COVID-19 can cause endless cycles of disease, which would be a bonanza for vaccine makers. Fashioning vaccines against COVID-19 would then be like chasing the wind.

    In one study only 14% of COVID-19 infected patients developed high concentration of neutralizing antibodies. Perplexingly, it has also been found that some COVID-19 infected patients who recovered completely did not develop detectable neutralizing antibodies, which suggests neutralizing antibodies may not be required to clear mild infections. Because of the limitation of vaccines against coronaviruses, alternatives to vaccines need to be pursued, which will be the topic of my next report.

    The origin of RNA vaccines

    To understand how modern medicine got on the wrong track we have to go back to the origins of RNA vaccines. Immune reactions to messenger RNA injections in animals weren’t safe. Animal experiments proved that. But in 2005 researchers announced they had replaced one of the four building blocks of messenger RNA, uridine, with pseudo-uridine, which evades immune sensors.

    Dendritic cells (cells that produce natural interferon) bathed in this modified pseudo-RNA produce less inflammation (cytokines) than when exposed to unmodified RNA. Voila! The possibility of RNA therapies began.

    Building an imperfect vaccine

    Vaccines that alleviate symptoms of infectious disease but don’t stop its spread (known as “leaky” vaccines) may result in more disease and more virulent strains of the virus. This has already been observed in chickens inoculated with a vaccine against Marek’s disease. Imperfect vaccination can enhance the transmission of viruses. Isn’t that what researchers did in 2005 – – intentionally develop an imperfect vaccine to avoid an over-aggressive immune response?

    Researchers writing in the Journal of Clinical & Experimental Hepatology say: “the greatest fear among vaccine developers is to create a vaccine that does not protect from infection but causes disease exacerbation, increased morbidity and mortality. Some vaccines can mount
    antibody-dependent enhancement (ADE),
    which negates the basic purpose of vaccination.”

    RNA vaccines are tailored to produce an antigen that triggers an immune response to a mutated coronavirus known as COVID-19. But COVID-19 is mutating, as all cold, flu and coronaviruses do. It appears vaccination is accelerating these mutations. Now what?

    RNA vaccines leave individuals defenseless

    RNA vaccines now being employed against COVID-19 aren’t as effective against genetic variants. Hence, reinfection can result. This has been known for some time. That leaves humanity back at square one, where it was at the beginning of the pandemic, facing a newly mutated coronavirus that humanity had no immunity towards (except those who had been vaccinated against tuberculosis with the BCG vaccine).

    Vaccine makers are scheming to make COVID-19 vaccinations an annual affair just like flu shots that are tailored for the three most likely flu strains expected to be in circulation in any given year. In other words, modern medicine is admitting it has created RNA vaccines that are not effective against evolving new strains. The virus is escaping vaccination.

    These facts reveal modern medicine and public health officials aren’t interested in cures as there already is a safe and effective vaccine. Governments and the medical industry aren’t interested in cures, they are interested in profits, political control and even depopulation.

    If you are losing sleep over the issue of vaccination, maybe take this report to your doctor and ask him/her to inoculate you with the BCG vaccine. Maybe the BCG vaccine will also suffice with employers who must be educated about this.

    I know I will be asked, so the answer to the question, am I going to the doctor to get a BCG vaccination? No, I am not. More than 96% of all individuals infected with COVID-19 get well on their own, without vaccines.

    Still, even with a safe and effective vaccine, all vaccines rely on an intact functioning immune system. The objective for those individuals who have been immunized with an RNA virus is to normalize their immune response. Certain essential nutrients are required to thwart the development of ADE if you are among the millions who have already been vaccinated with an RNA virus. That is the topic of my next report.

Comments are closed.